Clinical studies
Omnipod DASH® System
Clinical Studies
Why are your patients asking about Omnipod?
Omnipod DASH® is Australia's only tubeless, waterproof* insulin pump that provides continuous delivery of insulin for up to 72 hours.
In a 12-week randomised controlled trial, Omnipod DASH demonstrated a reduction in HbA1c of 0.4% and diabetes distress compared to usual care (MDI/CSII)1.
In real world Australian data of 241 Australians living with type 1 diabetes using Omnipod DASH®, users reported a reduction in HbA1c of 0.5% after three months (p<0.0001)2.
How the Omnipod DASH® System may help improve glycaemic control
How the Omnipod DASH® System may help improve Quality of Life
Association with a reduction in acute complications
Tubeless
The #1 Reason Australians Living With T1D Switch To Omnipod DASH®2
Study description
95% Of Australian
Adults interviewed with T1D using Omnipod DASH® would recommend it to others for T1D management3.
Study description
Omnipod DASH Users
experience a reduction in HbA1c and diabetes distress compared to usual care (MDI/CSII)1.
Study description
Important Safety Information: The Omnipod DASH®Insulin Management System is intended for subcutaneous delivery of insulin at set and variable rates for the management of diabetes mellitus in persons requiring insulin. The Omnipod DASH® System has been tested and found to be safe for use with the following U-100 insulin: Novolog®, Humalog®, Apidra®Fiasp®or Admelog®. Refer to the Omnipod DASH® Insulin Management System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.
1. Kong YW, et al. Treatment satisfaction with Omnipod DASH in adults with type 1 diabetes: A non-blinded 1:1 randomized controlled trial. J Clin Endocrinol Metab. DOI: https://doi.org/10.1210/clinem/dgae088. Published online 19 Feb 2024. A randomised controlled trial of 65 Adults with type 1 diabetes in Australia. 3 months randomisation to either Omnipod DASH® or usual care (MDI:60%/CSII:40%). Primary outcome: treatment satisfaction assessed by change in current Diabetes Technology Questionnaire (DTQ) score. HbA1c, CGM metrics and other questionnaires were also measured. Change in HbA1c (%), Omnipod DASH® -0.4 v usual care -0.1 (P= 0.037). This study received financial and in-kind support from Insulet Corporation. 2. Nash B, et al. Real-world Outcomes of a Tubeless Insulin Management System in 241 Australians living with Type 1 Diabetes. Presented at ATTD. Mar 6-9, 2024. Florence, Italy. 241 children and adults using Omnipod DASH. Baseline HbA1c was 7.4%. This study was sponsored by Insulet Corporation. 3. Stocco et al “You can hide it if you want to, you can let it be seen if you want to”: A qualitative study of the lived experiences of Australian adults with type 1 diabetes using the Omnipod DASH® system. Diabetes Research and Clinical Practice 208 (2024) 111123. 58 persons in semi-structured interviews were conducted with adults with T1D who participated in a parallel randomised clinical trial (N=65). All participants were interviewed by research nurses after 12-weeks of using an Omnipod DASH®.